Stock Analysis
- India
- /
- Personal Products
- /
- NSEI:EMAMILTD
Emami Limited (NSE:EMAMILTD) Just Reported, And Analysts Assigned A ₹716 Price Target
It's been a good week for Emami Limited (NSE:EMAMILTD) shareholders, because the company has just released its latest quarterly results, and the shares gained 2.3% to ₹573. The result was positive overall - although revenues of ₹10b were in line with what the analysts predicted, Emami surprised by delivering a statutory profit of ₹6.39 per share, modestly greater than expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
Check out our latest analysis for Emami
After the latest results, the 27 analysts covering Emami are now predicting revenues of ₹41.5b in 2026. If met, this would reflect a notable 11% improvement in revenue compared to the last 12 months. Statutory earnings per share are predicted to step up 17% to ₹21.32. In the lead-up to this report, the analysts had been modelling revenues of ₹42.2b and earnings per share (EPS) of ₹21.60 in 2026. The consensus analysts don't seem to have seen anything in these results that would have changed their view on the business, given there's been no major change to their estimates.
With no major changes to earnings forecasts, the consensus price target fell 7.4% to ₹716, suggesting that the analysts might have previously been hoping for an earnings upgrade. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. The most optimistic Emami analyst has a price target of ₹926 per share, while the most pessimistic values it at ₹510. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.
Looking at the bigger picture now, one of the ways we can make sense of these forecasts is to see how they measure up against both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of Emami'shistorical trends, as the 8.7% annualised revenue growth to the end of 2026 is roughly in line with the 7.6% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 7.5% annually. It's clear that while Emami's revenue growth is expected to continue on its current trajectory, it's only expected to grow in line with the industry itself.
The Bottom Line
The most obvious conclusion is that there's been no major change in the business' prospects in recent times, with the analysts holding their earnings forecasts steady, in line with previous estimates. They also reconfirmed their revenue estimates, with the company predicted to grow at about the same rate as the wider industry. Furthermore, the analysts also cut their price targets, suggesting that the latest news has led to greater pessimism about the intrinsic value of the business.
With that in mind, we wouldn't be too quick to come to a conclusion on Emami. Long-term earnings power is much more important than next year's profits. We have forecasts for Emami going out to 2027, and you can see them free on our platform here.
You should always think about risks though. Case in point, we've spotted 1 warning sign for Emami you should be aware of.
Valuation is complex, but we're here to simplify it.
Discover if Emami might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NSEI:EMAMILTD
Emami
Manufactures and markets personal and healthcare products in India and internationally.